^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SII OncoBCG (BCG vaccine)

    i
    Other names: BCG vaccine
    Associations

    News

    Trials
    Company:
    Serum Institute of India
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    7ms
    Diminishing of Helicobacter pylori adhesion to Cavia porcellus gastric epithelial cells by BCG vaccine mycobacteria. (PubMed, Sci Rep)
    Mycobacterium bovis onco-BCG bacilli used in immunotherapy of bladder cancer are candidates for training of immune cells towards microbial pathogens...Decrease of MUC5AC driven in cell cultures in vitro and in gastric tissue exposed ex vivo to mycobacteria was related to diminished adhesion of H. pylori bacilli. Vaccine mycobacteria by diminishing the amount of MUC5AC in gastric epithelial cells may reduce Hp adhesion.
    Journal
    |
    MUC5AC (Mucin 5AC)
    |
    SII OncoBCG (BCG vaccine)
    1year
    Mycobacterium bovis BCG increase the selected determinants of monocyte/macrophage activity, which were diminished in response to gastric pathogen Helicobacter pylori. (PubMed, Sci Rep)
    Bacillus Calmette-Guerin (BCG) vaccine with Mycobacterium bovis (Mb) is a candidate for modulation the activity of immunocompetent cells, and onco-BCG formulation was successfully used in immunotherapy of bladder cancer...Preliminary results indicate that BCG mycobacteria may also induce the phagocytosis of H. pylori by THP-1 monocytes. Priming or priming and restimulation of monocytes/macrophages with BCG resulted in an increased activity of these cells, which was negatively modulated by Hp.
    Journal • IO biomarker
    |
    CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • ITGB2 (Integrin Subunit Beta 2)
    |
    SII OncoBCG (BCG vaccine)